Consensus Report
GLP-1 Agonists
Moderate Consensus
out of 5
Based on 61 videos (84 hours analyzed) across the experts · Updated 2026-06-29
Stance update (Jun 2026): The next-generation triple agonist retatrutide (GLP-1 + GIP + glucagon) posted its pivotal Phase 3 results at the American Diabetes Association's June 2026 Scientific Sessions (TRIUMPH-1): an average ~25% body-weight loss at the top 12 mg dose over 80 weeks, climbing to ~30% by week 104, with more than a quarter of participants losing ≥35% — territory previously reached only by bariatric surgery. It remains investigational (not FDA-approved). Our panel hasn't covered retatrutide directly yet, but Attia's core caution scales with it: the faster and deeper the weight loss, the harder lean mass must be defended with protein and resistance training.
Stance update (Dec 2025 – Apr 2026): Oral GLP-1s went from 'in development' to FDA-approved. Oral semaglutide (the Wegovy pill, approved Dec 2025) delivered ~16.6% mean weight loss in the OASIS 4 trial but must be taken on an empty stomach with a 30-minute fast; Eli Lilly's orforglipron (approved Apr 2026) is a non-peptide small-molecule pill with no food-or-water restriction. Pills answer the 'needle fatigue' driving much of the current search interest, though the weekly injectables still lead on peak efficacy.
Expert Positions
The Verdict
This is one of the most polarizing topics across our expert panel. Attia and Huberman see GLP-1 agonists as powerful tools when combined with exercise and high protein intake, while Hyman strongly opposes their widespread use, arguing they mask root causes and create pharmaceutical dependency. This is a prescription medication, not a supplement — use requires physician oversight.
Where They Disagree
Attia views GLP-1 agonists as powerful, appropriate tools for weight management when combined with exercise and nutrition — while Hyman argues they mask root causes, create lifelong pharmaceutical dependency, and do not address the toxic food environment driving metabolic disease.
Attia's position on GLP-1s has evolved significantly over time and he now sees them more favorably, while Hyman has become increasingly critical, particularly regarding their use in children and as a substitute for dietary intervention.
+ 2 more disagreements in the full report
About This Analysis
This consensus report on GLP-1 Agonists is based on 61 videos (84 hours analyzed) from five longevity experts: Andrew Huberman, Peter Attia, Rhonda Patrick, Bryan Johnson, and Mark Hyman. Each expert's position was independently analyzed from their published video content, including lectures, podcast episodes, and Q&A sessions with 1,000+ guest scientists.
The full report includes 12 key findings, dosage and protocol details, expert deep dives with direct video citations and timestamps, risk considerations, and related supplement synergies.
Frequently Asked Questions
What do experts agree on about glp-1 agonists?
This is one of the most polarizing topics across our expert panel. Attia and Huberman see GLP-1 agonists as powerful tools when combined with exercise and high protein intake, while Hyman strongly opposes their widespread use, arguing they mask root causes and create pharmaceutical dependency.
Where do the experts disagree on glp-1 agonists?
Attia views GLP-1 agonists as powerful, appropriate tools for weight management when combined with exercise and nutrition — while Hyman argues they mask root causes, create lifelong pharmaceutical dependency, and do not address the toxic food environment driving metabolic disease. Attia's position on GLP-1s has evolved significantly over time and he now sees them more favorably, while Hyman has become increasingly critical, particularly regarding their use in children and as a substitute for dietary intervention. On the question of muscle loss: Attia acknowledges it as a serious but manageable risk with proper protein and training protocols, while Hyman and Patrick's guest (Dr. Bikman) frame it as a fundamental problem that undermines the drugs' value.
How strong is the expert consensus on glp-1 agonists?
The consensus on glp-1 agonists scores 2.6/5 — a moderate level of agreement across Huberman, Attia, Patrick, Johnson, and Hyman, based on their public videos.
Common Questions
Related Reports
Unlock the Full Report
Get dosages, timing protocols, expert deep dives with video citations, and risks for GLP-1 Agonists.
Every recommendation traces back to a specific expert, video, and timestamp.
$9/month or $79/year · Cancel anytime